Adalimumab biosimilar - Boehringer Ingelheim

Drug Profile

Adalimumab biosimilar - Boehringer Ingelheim

Alternative Names: BI-695501

Latest Information Update: 22 Mar 2017

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Rheumatoid arthritis
  • Phase III Crohn's disease; Plaque psoriasis

Most Recent Events

  • 01 Mar 2017 Boehringer Ingelheim completes a phase I trial in Healthy volunteers in Belgium and the Netherlands (SC) (NCT02899338)
  • 18 Jan 2017 Preregistration for Rheumatoid arthritis (In adults, In the elderly) in European Union prior to January 2017 (SC)
  • 18 Jan 2017 Preregistration for Rheumatoid arthritis prior to January 2017 (In the elderly, In adults) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top